RAF1 and cancer: However, the inability of type I1⁄2 inhibitors to fully inhibit homo‐ and hetero‐dimer RAF kinases is a primary mechanism of drug resistance in cancers with sustained RAS‐GTP signaling, including EGFR‐driven signaling in BRAFV600E/K colorectal cancer.